Refractory Hematologic Cancer

Refractory Hematologic Cancer, also known as refractory hematologic malignancy, is related to refractory hairy cell leukemia and b-cell prolymphocytic leukemia. An important gene associated with Refractory Hematologic Cancer is CD22 (CD22 Molecule), and among its related pathways/superpathways are Signaling by NTRKs and BCR signaling pathway. The drugs Cyclophosphamide and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include bone marrow and bone, and related phenotype is cellular.